NCT02778763View on ClinicalTrials.gov

Study on Efficacy and Safety of CBLB612 for Neutropenia Prophylaxis

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions
Breast Cancer
Interventions
DRUG

CBLB612

4 μg CBLB612 SQ

DRUG

Placebo

Sponsors

Collaborators (1)

Cleveland BioLabs, Inc.
All Listed Sponsors
collaborator

Cleveland BioLabs, Inc.

INDUSTRY

lead

BioLab 612 LLC

INDUSTRY